# TANTALUS Therapy in Type 2 Diabetic Patients Intolerant or Inadequately Responsive to GLP-1 Receptor Agonist Therapy

> **NCT01303315** · NA · TERMINATED · sponsor: **MetaCure (USA), Inc.** · enrollment: 20 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DEVICE:** TANTALUS System

## Key facts

- **NCT ID:** NCT01303315
- **Lead sponsor:** MetaCure (USA), Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-01
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Company strategic decision
- **Last updated:** 2016-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01303315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01303315, "TANTALUS Therapy in Type 2 Diabetic Patients Intolerant or Inadequately Responsive to GLP-1 Receptor Agonist Therapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01303315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*